- Home
- BIAF vs ABP Comparison
BIAF vs ABP Comparison
Compare BIAF & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- ABP
- Stock Information
- Founded
- BIAF 2014
- ABP 2004
- Country
- BIAF United States
- ABP United States
- Employees
- BIAF N/A
- ABP N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- ABP Health Care
- Exchange
- BIAF Nasdaq
- ABP Nasdaq
- Market Cap
- BIAF 12.2M
- ABP 12.3M
- IPO Year
- BIAF 2022
- ABP N/A
- Fundamental
- Price
- BIAF $0.35
- ABP $0.27
- Analyst Decision
- BIAF Hold
- ABP Strong Buy
- Analyst Count
- BIAF 1
- ABP 1
- Target Price
- BIAF N/A
- ABP $4.00
- AVG Volume (30 Days)
- BIAF 12.3M
- ABP 12.7M
- Earning Date
- BIAF 08-13-2025
- ABP 08-18-2025
- Dividend Yield
- BIAF N/A
- ABP N/A
- EPS Growth
- BIAF N/A
- ABP N/A
- EPS
- BIAF N/A
- ABP N/A
- Revenue
- BIAF $8,809,228.00
- ABP $183,000.00
- Revenue This Year
- BIAF N/A
- ABP N/A
- Revenue Next Year
- BIAF $20.00
- ABP N/A
- P/E Ratio
- BIAF N/A
- ABP N/A
- Revenue Growth
- BIAF 78.40
- ABP 88.66
- 52 Week Low
- BIAF $0.16
- ABP $0.15
- 52 Week High
- BIAF $2.99
- ABP $11.19
- Technical
- Relative Strength Index (RSI)
- BIAF 56.35
- ABP N/A
- Support Level
- BIAF $0.27
- ABP N/A
- Resistance Level
- BIAF $0.38
- ABP N/A
- Average True Range (ATR)
- BIAF 0.04
- ABP 0.00
- MACD
- BIAF 0.01
- ABP 0.00
- Stochastic Oscillator
- BIAF 73.43
- ABP 0.00
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.